Articular Cartilage Defect
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
VericelCAMBRIDGE, MA
1 programautologous cultured chondrocytes on porcine collagen membranePHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Vericelautologous cultured chondrocytes on porcine collagen membrane
Laurent PharmaceuticalsMACT
Clinical Trials (2)
Total enrollment: 224 patients across 2 trials
Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee
Start: Jul 2008Est. completion: Mar 2012144 patients
Phase 3Completed
Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee
Start: Dec 2026Est. completion: Jun 203280 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.